Published in Hepatitis Weekly, April 12th, 2004
Developed by leading hepatologists at the Pitie-Salpetriere Hospital and BioPredictive in France, HCV FibroSURE is only available in the United States through LabCorp.
HCV FibroSURE provides an accessible alternative to liver biopsy, which physicians use to assess liver fibrosis and necroinflammatory activity in HCV patients. While liver biopsy has long been considered the gold standard to monitor the status of HCV and determine therapy options, it is an invasive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.